Hepcidin and GDF15 in anemia of multiple myeloma.
Mei S et al. Int J Hematol. 2014 Jul 23. [Epub ahead of print].
Altered cytokine and chemokine profiles in multiple myeloma and precursor disease.
Zingone A et al. Cytokine. 2014 Jul 17. pii: S1043-4666(14)00150-1. doi: 10.1016/j.cyto.2014.05.017. [Epub ahead of print].
Detecting monoclonal light chains in urine: microLC-ESI-Q-TOF mass spectrometry compared to immunofixation electrophoresis.
Botz CM et al. Br J Haematol. 2014 Jul 7. doi: 10.1111/bjh.13003. [Epub ahead of print].
Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer.
D’Huyvetter M et al. Expert Opin Drug Deliv. 2014 Jul 18:1-16. [Epub ahead of print].
Imaging of multiple myeloma: Current concepts.
Derlin T et al. World J Orthop. 2014 Jul 18;5(3):272-82. doi: 10.5312/wjo.v5.i3.272. eCollection 2014.
Automated alarm to detect antigen excess in serum free immunoglobulin light chain kappa and lambda assays.
Urdal P et al. Scand J Clin Lab Invest. 2014 Jul 9:1-7. [Epub ahead of print].
Non osseous incidental findings in low dose whole body CT in patients with multiple myeloma.
Surov A et al. Br J Radiol. 2014 Jul 9:20140185. [Epub ahead of print].
Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma.
Brown R et al. Leukemia. 2014 Jul 3. doi: 10.1038/leu.2014.204. [Epub ahead of print].
A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents.
Iriuchishima H et al. Eur J Haematol. 2014 Jun 30. doi: 10.1111/ejh.12407. [Epub ahead of print].